Senhwa Biosciences receives ODD for Silmitasertib from FDA to treat biliary tract cancer

ODD status is given to those drugs and biologics meant for treatment, prevention or diagnosis of a life-threatening or chronically debilitating rare disease. Credit: Michal Jarmoluk from Pixabay